Lantern Pharma announces collaboration with Oregon Therapeutics to advance AI-driven cancer drug development

Lantern Pharma Inc. (NASDAQ: LTRN) announced a strategic collaboration with French biotech company Oregon Therapeutics to enhance the development of XCE853, a first-in-class protein disulfide ... Read More